Investigating how immune responses during cancer treatment can lead to kidney injury
Antigen-specific T cells in immunotherapy-associated acute kidney injury
This study is looking at how immunotherapy, a popular cancer treatment, can sometimes harm the kidneys, and it aims to find ways to prevent this damage so that patients can continue their cancer treatment safely.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11170211 on NIH RePORTER |
What this research studies
This research focuses on understanding how immunotherapy, a common cancer treatment, can inadvertently cause kidney damage, specifically acute kidney injury. The study aims to identify the immune cells and specific kidney-related antigens involved in this adverse effect. By analyzing the mechanisms behind this kidney injury, the researchers hope to develop targeted therapies that can prevent or mitigate these harmful immune responses without compromising cancer treatment. Patients receiving immunotherapy who experience kidney issues may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving immunotherapy and experiencing or at risk of acute kidney injury.
Not a fit: Patients who are not undergoing immunotherapy or those without kidney issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that protect kidney function in patients undergoing immunotherapy for cancer.
How similar studies have performed: Previous research has shown that understanding immune responses can lead to better management of treatment-related side effects, suggesting potential for success in this area.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Murakami, Naoka — Washington University
- Study coordinator: Murakami, Naoka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.